Navigation Links
NeoVista, Inc. Presents New Data on Its Novel Wet AMD Therapy at AAO
Date:11/12/2007

this study demonstrated its differences from previous attempts by the medical community to use radiation for the treatment of wet AMD. Additional on-going studies may well confirm the viability of this new therapeutic option for the elderly with wet AMD."

Unlike previous forms of radiation therapy for Wet AMD, NeoVista's approach delivers the peak dose of radiation directly to the lesion without damaging the underlying choroidal vasculature. Utilizing strontium-90, the focused radiation is delivered to a target area 3 mm in depth and up to 5.4 mm in diameter. Importantly for patients, the systemic exposure to radiation is minimal, as the effective dose to the entire body from NeoVista's epiretinal device is comparable to 15 minutes of exposure to the sun.

"The ultimate promise of this therapy revolves around that fact that NeoVista's targeted radiation delivery system allows patients to continue living their lives, with significantly less injections, while also having the potential to save both patients and the healthcare system billions of dollars," said John N. Hendrick, President and CEO of NeoVista. "We look forward to unveiling the true impact of our therapy on patients and physicians now that our larger CABERNET trial is underway."

The CABERNET (CNV Secondary to AMD Treated with BEta RadiatioN Epiretinal Therapy) trial is a multi-center, randomized, controlled study which will enroll 450 subjects at 30 sites worldwide (20 in the United States). The study will evaluate the safety and efficacy of NeoVista's beta radiation epiretinal therapy delivered concomitantly with the FDA approved antiangiogenic therapy, Lucentis(R), versus Lucentis(R) alone.

About NeoVista, Inc.

NeoVista, Inc. is a privately held development-stage medical device company based in Fremont, California. NeoVista's beta radiation epiretinal therapy is currently being studied in a definitive clinical study to support eventual filing for regulatory approval to market
'/>"/>

SOURCE NeoVista, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014   Ventana Medical Systems, ... announced it has entered into an agreement with Merck ... as EMD Serono in the United States ... collaborate with Merck KGaA,s biopharmaceutical division on the development ... undisclosed target using Ventana,s proprietary diagnostic assays. In alignment ...
(Date:7/10/2014)... , July 10, 2014 CVS Caremark Corporation (NYSE: ... directors has approved a quarterly dividend of $0.275 (27.5 cents) ... payable on August 1, 2014, to holders of record on ... CVS Caremark is dedicated to helping people on their ... in the United States . Through the ...
(Date:1/15/2014)... ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry Report, 2013-2015" research ... http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting from aging of ... orthopedic instrument industry has seen rapid development ... 3.28 billion yuan in 2006 to 9.85 billion yuan ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3
(Date:7/13/2014)... Recently, MillionaireCasket.com, a well-known casket manufacturer from China, has announced ... company’s chief executive officer has announced a new promotion for ... at discounted prices, from 15 to 26 percent off. , ... huge demand in the current market. We are excited to ... lot of high quality products for sale. Many of our ...
(Date:7/13/2014)... Micro irrigation systems are mainly utilized for agriculture in ... to maintain soil quality. The application of micro irrigation ... revenue generator for manufacturers in future. The trend of ... led to the adoption of micro irrigation techniques for ... demand for micro irrigation systems, as they reduce the ...
(Date:7/13/2014)... July 13, 2014 Fuel additives are ... gasoline, diesel, jet fuel, kerosene, and so on, in ... responsible for reducing the corrosion effects caused by fuels ... added to any fuel, provide economies of scale in ... escalate the overall cost of the fuel products. , ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 A Massachusetts ... to the cancer risks associated with power morcellators ( ... their story to federal regulators, as they presented poignant ... Food & Drug Administration (FDA) advisory panel meeting convened ... According to the Rochester Democrat and Chronicle, Dr. Hooman ...
(Date:7/13/2014)... Athletes with a certain genetic make-up are ... to research presented today at the American Orthopaedic Society ... research marks the first of its kind investigating a ... events that occur after a head injury. , ... the (GT)n genotype were four times more likely to ...
Breaking Medicine News(10 mins):Health News:Cheap Oak Caskets Recently Unveiled By China Casket Manufacturer MillionaireCasket.com 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2
... 27 One of the nation,s,largest pharmacy benefits ... and 28 other states resolving claims of,deceptive business ... agreement was reached with,Express Scripts Inc., a pharmacy ... nationwide., As part of the settlement, Express ...
... In a first-of-its-kind study in osteoporosis, one in four women ... or more bone fractures since the age of 45 years. ... a fracture, only 26% reported use of bone-saving drugs, with ... America and Australia. Identifying important regional differences is just ...
... 27 The,Biomedical Excellence for Safer Transfusion (BEST) ... validity and medical,implications of several recent papers purporting ... Blood Cells leads to greater risk. The organization,will ... Health and Human,Services (HHS) meeting of the Advisory ...
... distribution of mineral in arteries rather than amount ... of a person,s heart attack risk can be achieved ... only the amount, but also the distribution, of calcified ... , "Now we know that the location of the ...
... Astrium GmbH have today signed a contract worth 263 ... Explorer mission of ESAs Living Planet Programme. As prime ... development and integration. , The contract was signed today ... Exhibition (ILA) by Volker Liebig, ESAs Director of Earth ...
... Expert To Discuss The Benefits of Improved Patient ... MedAssurant, Inc., a leading,medical informatics solutions provider, announced ... will be presenting at AHIP,s,Institute 2008 to be ... West in,San Francisco., The symposium, "Patient Healthcare ...
Cached Medicine News:Health News:Pennsylvania Attorney General Corbett Announces Multi-State Settlement With Express Scripts Inc. 2Health News:Pennsylvania Attorney General Corbett Announces Multi-State Settlement With Express Scripts Inc. 3Health News:Global study reveals differences in standard of care for osteoporosis across the world 2Health News:International Research Organization Responds to Recent Studies Purporting to Show That Transfusion of Older Red Blood Cells Leads to Greater Risk 2Health News:International Research Organization Responds to Recent Studies Purporting to Show That Transfusion of Older Red Blood Cells Leads to Greater Risk 3Health News:New Calcium Measure Better Predictor of Heart Risks 2Health News:EarthCARE satellite contract signed 2Health News:MedAssurant's Dr. Keith Dunleavy to Present at AHIP's Institute 2008 2
The Pan Retinal® 2.2 uniquely combines magnification nearly that of the 20D lens with a field of view approaching that of the 30D lens. Excellent for virtually every examination procedure, includ...
The 14D provides high magnification along with an optimized working distance from the cornea. With its 4.30x magnification, it is also well suited for optic disc and macular observation....
This excellent mid-power lens provides medium field and magnification, with an ideal diameter for grip andmanipulation in the orbital area....
The Professional ophthalmoscope has been designed to ensure ultimate control. Lenses, graticules and filters can all be introduced at the touch of a fingertip without the need to pull away from the p...
Medicine Products: